You are here

uniQure

After Hemgenix approvals, uniQure cashes out some of its royalty rights for $375M-plus

After Hemgenix approvals, uniQure cashes out some of its royalty rights for $375M-plus

Fierce Pharma

Flag link:

Major readouts on the horizon for small developers

Major readouts on the horizon for small developers

EP Vantage

Aldeyra Therapeutics

Autolus Therapeutics

Bavarian Nordic

BioXcel Therapeutics

Editas Medicine

Mersana Therapeutics

NGM Biopharmaceuticals

Sutro BioPharma

Viking Therapeutics

Flag link:

Big pharma’s new year catalysts

Big pharma’s new year catalysts

EP Vantage

Flag link:

Bristol Myers has change of heart on cardiovascular gene therapy pact, terminating uniQure deal

Bristol Myers has change of heart on cardiovascular gene therapy pact, terminating uniQure deal

Fierce Biotech

Bristol Myers Squibb

Flag link:

uniQure, CSL claim first okay for hemophilia B gene therapy

uniQure, CSL claim first okay for hemophilia B gene therapy

Pharmaphorum

Flag link:

UniQure revs up engines again for Huntington's gene therapy after trial hospitalizations

UniQure revs up engines again for Huntington's gene therapy after trial hospitalizations

Fierce Biotech

Huntington's disease

Flag link:

uniQure pauses part of Huntington's trial after 3 patients hospitalized—1 of whom hasn’t fully recovered

uniQure pauses part of Huntington's trial after 3 patients hospitalized—1 of whom hasn’t fully recovered

Fierce Biotech

clinical trials

Huntington's disease

Flag link:

uniQure shares spike as investors see bright spot in 12-month Huntington's gene therapy data

uniQure shares spike as investors see bright spot in 12-month Huntington's gene therapy data

Fierce Biotech

Huntington's disease

Flag link:

CSL-UniQure Hemophilia B Gene Therapy Scores Priority Review

CSL-UniQure Hemophilia B Gene Therapy Scores Priority Review

BioSpace

priority review

etranacogene dezaparvovec

Flag link:

As biotech retreats, gene therapy companies retrench and redraw plans

As biotech retreats, gene therapy companies retrench and redraw plans

BioPharma Dive

Flag link:

Fresh data show UniQure's hemophilia gene therapy appears to hold up

Fresh data show UniQure's hemophilia gene therapy appears to hold up

BioPharma Dive

Flag link:

Biotech M&A tracker: After hitting new heights, deals have slowed down. Here are the latest.

Biotech M&A tracker: After hitting new heights, deals have slowed down. Here are the latest.

BioPharma Dive

Xeris Pharmaceuticals

Relay Therapeutics

Beam Therapeutics

Jazz Pharmaceuticals

Flag link:

Gene therapy for Fabry: early stages, promising results

Gene therapy for Fabry: early stages, promising results

BioPharma Dive

Freeline Therapeutics

Sangamo Therapeutics

Flag link:

Late-Stage Clinical Study Readouts Biotech Investors Should Watch

Late-Stage Clinical Study Readouts Biotech Investors Should Watch

Motley Fool

clinical trials

SAGE Therapeutics

Flag link:

Biopharma takeovers dry up

Biopharma takeovers dry up

EP Vantage

Constellation Pharmaceuticals

Tidal Therapeutics

Corlieve Therapeutics

Strongbridge Biopharma

Xerix Pharmaceuticals

Novellus Therapeutics

Brooklyn Immunotherapeutics

Flag link:

With FDA filing for key gene therapy pushed back 6 months, uniQure opens the pocketbook to refresh the pipeline

With FDA filing for key gene therapy pushed back 6 months, uniQure opens the pocketbook to refresh the pipeline

Endpoints

Corlieve Therapeutics

temporal lobe epilepsy

Flag link:

UniQure moves Huntington's gene therapy to next phase of key trial

UniQure moves Huntington's gene therapy to next phase of key trial

BioPharma Dive

Huntington's disease

clinical trials

Flag link:

FDA lifts clinical hold on uniQure's gene therapy amid cancer concerns; shares jump

FDA lifts clinical hold on uniQure's gene therapy amid cancer concerns; shares jump

Fierce Biotech

Flag link:

Pages